Sagent Pharmaceuticals, Inc. has launched doxorubicin hydrochloride injection, USP, an antineoplastic agent, in three vial presentations. According to IMS, for the 12 months ending September 2013, the US market for doxorubicin hydrochloride injection, USP approximated $14 million.

As with all products in Sagent's portfolio, doxorubicin features Sagent's PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors.

Doxorubicin hydrochloride injection has been used successfully to produce regression in disseminated neoplastic conditions such as acute lymphoblastic leukaemia, acute myeloblastic leukaemia, Wilms' tumour, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin's disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.

Sagent Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables.